Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05120934 · ClinicalTrials.gov registry record · Phase 2

Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough

A Phase 2 study of Interstitial Lung Disease, sponsored by Mayo Clinic.

Recruiting
Registry status
Phase 2
Development phase
25
Enrollment target
1
Study location

NCT05120934: Recruiting Phase 2 study of Interstitial Lung Disease, sponsored by Mayo Clinic.

NCT05120934 is a Phase 2 study of Interstitial Lung Disease that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 25 participants, below the 566-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05120934, a Phase 2 study of Interstitial Lung Disease, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
Phase 2
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with interstitial lung disease (ILD)-related cough.

Conditions Studied

Interstitial Lung Disease

Interventions

  • DRUG Duloxetine 30 MG
  • DRUG Amitriptyline 25 MG
  • DRUG Amitriptyline 50 MG
  • DRUG Duloxetine 60 MG
  • DRUG Placebo 30 MG

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2021-11-01
Est. Completion 2026-10
Phase Phase 2

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05120934

The ClinicalTrials.gov registry entry for NCT05120934 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 566-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (96% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Interstitial Lung Disease appearing as the primary indexed condition, and to 5 interventions - of which Duloxetine 30 MG is the first listed.

NCT05120934 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT05120934 about?

NCT05120934 is a clinical study titled "Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough". This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with interstitial lung disease (ILD)-related cough.

What is the current status of trial NCT05120934?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-11-01. Estimated completion is 2026-10.

What conditions does trial NCT05120934 study?

This clinical trial studies the following conditions: Interstitial Lung Disease.

What interventions are being tested in trial NCT05120934?

The interventions under investigation include: Duloxetine 30 MG (DRUG), Amitriptyline 25 MG (DRUG), Amitriptyline 50 MG (DRUG), Duloxetine 60 MG (DRUG), Placebo 30 MG (DRUG).

Who is sponsoring clinical trial NCT05120934?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05120934 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Interstitial Lung Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Interstitial Lung Disease

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.